The most intensively studied IL-7R agonist now in development is the PK-enhanced IL-7 efineptakin alfa, previously shown to suppress tumor growth in preclinical murine tumor models, both as monotherapy and in combination with a PD-1 CPI. Here, IL7R is linked to neoplasm.